ASCO 2024 | Key takeaways from ASCO 2024: advances in kidney cancer biomarkers and neoadjuvant therapy
Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses key takeaways from the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. Prof. Powles highlights promising developments in kidney cancer biomarkers, particularly Kim-1, which may enhance treatment strategies. However, the most notable data came from the randomized Phase III NADINA trial (NCT04949113) comparing adjuvant versus neoadjuvant immune therapy, which revealed a benefit for the neoadjuvant approach, suggesting a potential shift in perioperative treatment strategies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
